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Nicotine [(S)-3-(1-methyl-2-pyrrolidinyl)pyridine] is a major component of tobacco and a highly efficient acetylcholine receptor
(nAChR) agonist that triggers the cholinergic anti-inflammatory pathway. We demonstrate that pre-treatment of monocytes with the stable
nicotine catabolite, cotinine [(S)-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone], dramatically alters the nature of the inflammatory response to
Gram negative bacteria by abrogating the production of cytokines that are under the transcriptional control of the NF-κB system (TNF-α,
IL-1β, IL-6, IL-12/IL-23 p40) and shifting the response towards an IL-10-dominated anti-inflammatory profile. This anti-inflammatory
phenomenon is initiated specifically by engagement of the monocytic α7 nAChR; and is PI3K/GSK-3β-dependent; but NF-κB-
independent. These mechanistic insights suggest an ability to exploit convergent, endogenous anti-inflammatory pathway(s) to either up-
regulate or down-regulate the production of specific cytokine groups (pro- or anti-inflammatory cytokines) depending on the clinical
necessity.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cholinergic anti-inflammatory pathway; Cotinine; Cytokine; Inflammation; Monocyte; PI3K-dependent anti-inflammatory pathway; Tobacco smoking1. Introduction
Components of Gram negative bacteria, and particularly
lipopolysaccharides (LPS), are potent inducers of the inflam-
matory response. LPS recruits, activates, and promotes degra-
nulation events in the most numerous inflammatory leukocyte,
the neutrophil. LPS and neutrophil degranulation products each
recruit monocytes and macrophages to the locus of infection.
While neutrophils are, in relative terms, short-lived and trans-
criptionally quiescent, monocytes/macrophages are longer-lived
cells that when stimulated by LPS, and other inflammatory
mediators, produce large amounts of pro-inflammatory cyto-
kines, including TNF, IL-1β, IL-6, IL-12/IL-23 p40, IL-18,
and HMGB-1 de novo. These macrophage-derived mediators
amplify and direct the inflammatory response and link the innate
and adaptive immune responses.⁎ Corresponding author. Tel.: +1 502 852 8905; fax: +1 502 852 4052.
E-mail address: dascot07@louisville.edu (D.A. Scott).
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.12.003The ability to regulate against prolonged or excessive in-
flammation is critical in preventing the onset of septic shock and
the host-mediated damage associated with multiple chronic
inflammatory diseases. However, the mechanisms that dictate
the establishment of pro- versus anti-inflammatory cytokine-
dominated environments are poorly understood. In recent years
it has become clear that the nicotinic acetylcholine receptor α7
subunit is a critical regulator of inflammation [1,2]. Acetyl-
choline, produced by the vagus nerve network, is an endoge-
nous α7 nAChR agonist. Acetylcholine and the exogenous α7
nAChR agonist, nicotine, both suppress the release of TNF-α
from activated cells of monocytic lineage and are protec-
tive against LPS-mediated toxicity [2–5]. Thus, nAChRs
and downstream components of the cholinergic anti-inflamma-
tory pathway present novel therapeutic targets for controlling
inflammatory diseases.
However, we are only beginning to understand the mechanisms
of action of acetylcholine and nicotine in innate immune sup-
pression. Furthermore, nicotine is rapidly converted into multiple
Fig. 1. Human monocytes treated with nicotine or cotinine produce significantly
less TNF-αwhen stimulatedwithP. gingivalis. Monocytes were pre-treated for 2 h
with nicotine (triangles) or cotinine (squares) then stimulated with P. gingivalis
(MOI=10) for 20 h. Cell-free supernatants were harvested by centrifugation and
levels of TNF-α were determined by ELISA. The alkaloid suppression of TNF
production is dose-dependent. Mean nicotine concentrations in smokers would be
expected to be in the region of 30 ng ml−1 with mean cotinine levels in smokers in
the region of 200–500 ng ml−1 [6]. Systemic cotinine levels of 1–15 ng ml−1 are
found in second-hand smokers [6]. P. gingivalis is a Gram negative periodontal
pathogen. Similar results are seen with E. coli and purified LPS (data not shown).
Data are the arithmetic mean±s.d. of 3 experiments. ⁎Indicates statistical
significance at pb0.05, as compared to cells stimulated with P. gingivalis alone.
Cotinine (0 to 105 ng ml−1) had no statistically significant effect on the viability of
primary monocytes, compared to P. gingivalis alone.
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nicotine have been extensively studied, the major proximate
metabolite – cotinine – has received relatively little attention. Yet,
cotinine is a much more stable molecule and systemic concentra-
tions approach ten fold that of nicotine [6].
Like nicotine, cotinine evokes striatal dopamine release [7];
appears to improve working memory and attention [8]; is neu-
roprotective [8]; and suppresses the release of free radicals from
neutrophils [9]. Thus, cotinine is clearly pharmacologically
active. However, cotinine is unlike nicotine in key physiological
aspects. Cotinine does not appear to up-regulate the expression
of nicotinic receptors in the brain [8]; it may not be vasoactive,
as monitored by changes in heart rate, blood pressure, or skin
temperature in response to cotinine infusions in humans [10,11];
it is considered non-addictive [12]; and the administration of
cotinine to humans at levels as high as 10 times than that attained
from cigarette smoking has been shown to be safe [12].
We hypothesized that because of the structural similarities
between nicotine (3-(1-methyl-2-pyrrolidinyl) pyridine) and coti-
nine (1-methyl-5-[3-pyridynl]-2-pyrrolidinone), cotinine would
have anti-inflammatory properties.
2. Materials and methods
2.1. Isolation and culture of primary monocytes
Whole human blood was purchased from Lampire Biological Laboratories
(Pipersville, PA). Primary monocytes were isolated by an indirect magnetic
monocyte isolation kit (Miltenyi Biotec, Auburn, CA) as we have previously
reported [13,14]. This procedure routinely results in N95% pure CD14+ cells, as
shown by flow cytometry. Human monocytes were cultured at 37 °C and 5%
CO2 atmosphere, in complete RPMI (RPMI 1640 supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin G,
100 µg/ml streptomycin, and 0.05 mM 2-mercaptoethanol [Invitrogen Life
Technologies, Carlsbad, CA]) plus or minus stimulating agents, as described
below.
2.2. Growth of Porphyromonas gingivalis
P. gingivalis ATCC 33277 was grown in modified Gifu anaerobic medium
(Nissui Pharmaceutical Company, Tokyo, Japan) under anaerobic conditions
(85% N2, 10% H2, 5% CO2) at 37 °C.
2.3. Cytokine release by monocytes
Mean nicotine concentrations in smokers would be expected to be in the
region of 30 ng ml−1 with mean cotinine levels in smokers in the region of 200–
500 ng ml−1 [6]. Systemic cotinine levels of 1–15 ng ml−1 are found in second-
hand smokers [6]. Primary monocytes were pre-treated with nicotine (0–100 ng
ml−1) or cotinine (0–1000 ng ml−1) then stimulated with the Gram negative
periodontal pathogen P. gingivalis (MOI=0–10); purified Escherichia coli K-
12 LPS (0–1 μg ml−1; InVivoGen, San Diego, CA); or purified P. gingivalis
33277 LPS for 20 h. Primary monocytes were also pre-treated with cotinine
(100 ng ml−1) then stimulated with increasing doses of LPS for 20 h. Cell-free
supernatants were harvested by centrifugation and cytokine levels (TNF, IL-1β,
IL-6, IL-10, IL-12/IL-23 p40, as appropriate) were determined by ELISA
(eBioscience, San Diego, CA or R&D Systems, Minneapolis, MN).
2.4. Expression of α7 nACh receptors
Total primary monocyte cell lysate (40 μg of protein) western blots were
probed with an anti-α7AChR specific antibody (Q4A163R, Biodesign Inter-
national, Saco, ME) recognizing amino acids 493–502 at the C terminus.
Promyelocytic HL-60 cells served as a positive control. Proteins recognized by
the anti-α7AChR specific antibody were detected by enhanced chemilumines-
cence (Amersham Biosciences, Piscataway, NJ).
2.5. NF-κB in cotinine-induced inflammatory suppression
THP-1 Blue cells are monocyte-like cells that have been stably transfected
with a reporter plasmid expressing secreted embryonic alkaline phosphatase
(SEAP) gene under the control of a NF-κB-inducible promoter. THP-1 and
THP-1 Blue cells (InVivoGen, San Diego, California) were pre-treated with
cotinine (100 ng ml−1) for 2 h then stimulated with E. coli LPS (1 μg ml−1) for
24 h. Cell-free supernatants were harvested by centrifugation and relative
expression levels of NF-κB and IL-10 were determined by spectrophotometric
analysis of SEAP activity and ELISA, respectively.
2.6. The cholinergic anti-inflammatory pathway in cotinine-induced
inflammatory suppression
The importance of α7 nAChR in cotinine-induced modulation of cytokine
release profiles was assessed using the selective nAChR antagonist, α-bun-
garotoxin (α-BTX; 2 μg ml−1; Sigma Chemical Company, St. Louis, MO). Of
the α-BTX-sensitive nAChRs, monocytes express only α7 nAChR [1,2,15,16].
2.7. The PI3K-dependent anti-inflammatory pathway in cotinine-induced
inflammatory suppression
Levels of phosphorylated Akt and phoshorylated GSK-3β following coti-
nine (0–100 ng ml−1) and/or E. coli LPS (1 μg ml−1) treatment were determined
by western blot using whole-cell lysates (20 μg) with probing for Akt using a
phospho-specific Akt (Ser473) antibody; probing for GSK-3β using a phospho-
specific GSK3-β (Ser9; denoted pGSK-3β) antibody; with the blots stripped and
re-probed for total p38 to ensure equivalent loading. Antibodies were purcha-
sed from Cell Signaling, Beverly, MA. Blots were visualized by enhanced
chemiluminescence. The importance of the PI3K-dependent anti-inflammatory
pathway in cotinine-induced inflammatory suppression was also established by
Fig. 2. Cotinine inhibits the production of multiple pro-inflammatory cytokines in P. gingivalis-stimulated human monocytes (A–D) but augments IL-10 production
(E). (A–E) Control monocytes (closed squares) and monocytes pre-treated with cotinine (100 ng ml−1) for 2 h (open squares) were stimulated with P. gingivalis 33277
LPS (0–105 ng ml−1) for 24 h. Cell-free supernatants were harvested by centrifugation and levels of pro-inflammatory cytokines (A–E) and IL-10 (E) were determined
by ELISA. Data are the arithmetic mean±s.d. of 3 experiments. Statistical significance was set at pb0.05, and cotinine altered the production of all cytokines tested, as
compared to cells stimulated with LPS alone. Cotinine (100 ng ml−1) had no statistically significant effect on the viability of primary monocytes, compared to LPS
alone.
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LY294002 (25 μM; Calbiochem, San Diego, CA) and wortmannin (100 nM,
Calbiochem); and the GSK-3β inhibitor SB216763 (6 μM; Sigma). ActivatedPI3K produces PIP3 that, in turn, activates downstream signaling components of
the PI3K pathway. Therefore, cells were also analyzed for cotinine-induced PI3K
activation by assaying the ability of PI3K to produce PIP3. Levels of PIP3 were
Fig. 3. α-Bungarotoxin treatment of α7AChR-expressing human monocytes
abrogates the anti-inflammatory effects of cotinine. (A) Total cell lysate (40μg of
protein) blots of primary monocytes (Lanes 2–4) and a positive control
(promyelocytic HL-60 cells; Lane 1) were probed with an anti-α7AChR specific
antibody (Q4A163R, Biodesign Intl.) recognizing amino acids 493–502 at the
C terminus. Monocytes expressed α7 nACh receptors with relative molecular
masses of 55 kDa. (B) Control monocytes (open squares) and monocytes pre-
treated for 30 min with the α7 nACHR antagonist α-BTX (2μg ml−1, closed
squares) were incubated for 2 h with various concentrations of cotinine. Cells
were then stimulated with P. gingivalis (MOI=10) for 20 h. Cell-free
supernatants were harvested by centrifugation and levels of TNF were
determined by ELISA. Data are the arithmetic mean±s.d. of 3 experiments.
⁎Indicates statistical significance at pb0.05, as compared to control cells.
Fig. 5. Cotinine (A) enhances Akt signaling and (B) augments levels of phos-
phorylated (Ser9) GSK3-β in P. gingivalis-stimulated monocytes. (A) Mono-
cytes were pre-treated for 2 h with cotinine then stimulated for 60 min with LPS
(1 mg ml−1). Western blot was performed using whole-cell lysates (20 μg)
with probing for Akt using a phospho-specific Akt (Ser473) antibody. Blot
was stripped and re-probed for total p38 to ensure equivalent loading. Lane 1:
Non-stimulated; Lane 2: LPS only; Lane 3: LPS+cotinine (100 ngml−1), Lane 4:
LPS+cotinine+wortmannin (a PI3K inhibitor, 100 nM). Data are representative
of three experiments. Similar results were seen with 60 min stimulations with
P. gingivalis (MOI=10; data not shown). (B) Monocytes were pre-treated for 2 h
with cotinine then stimulated for 60 min with LPS (1 mgml−1). Western blot was
performed using whole-cell lysates (20 μg) with probing for GSK-3β using a
phospho-specific GSK3-β (Ser9; denoted pGSK3) antibody. Blot was stripped
and re-probed for total p38 to ensure equivalent loading. Lane 1: Non-stimulated;
Lane 2: LPS only; Lane 3: LPS+cotinine (10 ng ml−1), Lane 4: LPS+cotinine
(100 ng ml−1). Data are representative of three experiments. Similar results were
seen with 60 min stimulations with P. gingivalis (MOI=10; data not shown).
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Salt Lake City, UT). The specific PI3K inhibitor LY294002 was used at 25 μM
and served as a control to block PI3K activity.Fig. 4. The anti-inflammatory potential of cotinine is a GSK-3β-dependent but
NF-κB-independent phenomenon. THP-1 Blue cells are stably transfected with a
reporter plasmid expressing secreted embryonic alkaline phosphatase (SEAP)
gene under the control of a NF-κB-inducible promoter. THP-1 and THP-1 Blue
cells were pre-treated with cotinine (100 ng ml−1) for 2 h then stimulated with
LPS (1 μgml−1) for 24 h. Cell-free supernatants were harvested by centrifugation
and relative expression levels of SEAP (reflecting NF-κB; THP-1 Blue; circles)
and IL-10 (THP-1; bars) were determined by spectrophotometric analysis of
SEAP activity and ELISA, respectively. Here we also show that the GSK-3β
inhibitor – SB216763 – enhances IL-10 production in response to LPS, but it is
less potent than even low doses of cotinine (10 ng ml−1; pb0.05). Induction of
NF-κB on stimulation with LPS is not influenced by cotinine treatment. All data
are the arithmetic mean±s.d. of 3 experiments. ⁎pb0.05; compared to
unstimulated cells. Cotinine (100 ng ml−1) had no statistically significant effect
on the viability of THP-1 or THP-1 Blue cells compared to LPS alone.2.8. Convergence of the cholinergic and PI3 kinase-dependent
anti-inflammatory pathways during cotinine-induced inflammatory
suppression
Interactions between the cholinergic and PI3 kinase-dependent anti-in-
flammatory pathways were examined by assessing the efficacy of α-BTX (2 μg
ml−1) to block activation of the PI3K pathway. PIP3 levels were monitored by
ELISA following 60 min with LPS (1 μg ml−1) in the presence and absence of
cotinine (0–100 ng ml−1).
2.9. Statistical approaches
Statistical significance between groups was evaluated by ANOVA and the
Tukey multiple-comparison test using the InStat program (GraphPad Software,
San Diego, CA). Differences between groups were considered significant at the
level of pb0.05.
3. Results
3.1. Cotinine inhibits TNF release
Cotinine is equally as effective as nicotine at inhibiting TNF
release (Fig. 1). Indeed cotinine blocks more than 80% of bacteria-
induced TNF release from monocytes at a dose of 100 ng ml−1
(Fig. 1), a level commonly observed in cigarette smokers [6].
3.2. Cotinine promotes an anti-inflammatory phenotype
Cotinine also dramatically suppresses the release of multiple
pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and the common
Fig. 6. Innate immune suppression by cotinine requires the α7 nAChR-
dependent enhancement of PI3K activation. (A) Inhibition of PI3K using
LY294002 abrogates the anti-inflammatory effects of cotinine. Cells were pre-
treated with (closed triangles) and without (closed squares) 25 μM of the PI3K
inhibitor LY294002 for 30 min followed by 2 h with various concentrations of
cotinine. Following 24 h P. gingivalis-stimulation (MOI=10), cell-free super-
natants were harvested by centrifugation and levels of TNF-α were determined
by ELISA. ⁎Indicates statistical significance at pb0.05, as compared to cells
stimulated with P. gingivalis alone (no LY294002). Data are the arithmetic
mean±s.d. of 3 experiments. All media used in these experiments contained
0.01% DMSO to act as the organic solvent control used to solubilize LY294002.
Similar results are also seen with the alternative PI3K inhibitor, wortmannin
(100 nM; data not shown). (B) Cotinine (or nicotine) treated monocytes exhibit
increased PIP3 levels when stimulated with LPS in an α7 nAChR-dependent
manner. Cells were stimulated for 60 min with 1 μg ml−1 of LPS. Cells were
analyzed for PI3K activation by the ability of PI3K to produce PIP3. Activated
PI3K produces PIP3 that, in turn, activates downstream signaling components of
the PI3K pathway. Levels of PIP3 were determined by ELISA using a
competitive inhibition assay (Echelon Bioscience). The specific PI3K inhibitor
LY294002 was used at 25 μM (cells were pre-treated for 1 h) and served as a
control to block PI3K activity. α7 nAchR-dependence was established through
the use of the α7 nAChR antagonist, α-bungarotoxin. ⁎Indicates statistical
significance at pb0.05, as compared to unstimulated control cells. ¶ Indicates
statistical significance at pb0.05, as compared to cells stimulated with LPS
alone. § Indicates statistical significance at pb0.05 for cells stimulated with
LPS, nicotine and LY294002 (or α-BTX) compared to LPS and nicotine only. †
Indicates statistical significance at pb0.05 for cells stimulated with LPS,
cotinine and LY294002 (or α-BTX) compared to LPS and cotinine only. Data
are the arithmetic mean±s.d. of 3 experiments.
Fig. 7. Enhancement of IL-10 release by cotinine requires the α7 nAChR-
dependent enhancement of PI3K activation. Inhibition of PI3K using LY294002
abrogates the anti-inflammatory effects of cotinine and nicotine, as assessed by
IL-10 release. Cells were pre-treated with and without the PI3K inhibitor
LY294002 (25 μM); and with or without α-bungarotoxin (2 μg ml−1) for
30 min, followed by 2 h with nicotine (100 ng ml−1) or cotinine (100 ng ml−1).
Following 24 h LPS stimulation (2 μg ml−1), cell-free supernatants were
harvested by centrifugation and levels of IL-10 were determined by ELISA.
⁎Indicates statistical significance at pb0.05, as compared to unstimulated
control cells. ¶ Indicates statistical significance at pb0.05, as compared to cells
stimulated with LPS alone. § Indicates statistical significance at pb0.05 for cells
stimulated with LPS, nicotine and LY294002 (or α-BTX) compared to LPS and
nicotine only. † Indicates statistical significance at pb0.05 for cells stimulated
with LPS, cotinine and LY294002 (or α-BTX) compared to LPS and cotinine
only. Data are the arithmetic mean±s.d. of 3 experiments.
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simultaneously enhancing production of the key anti-inflammatory
cytokine, IL-10 (Fig. 2E).3.3. Cotinine-induced inflammatory suppression likely occurs
via α7 nAChR
Of the α-bungarotoxin sensitive human nAChRs (α1, α7,
and α9), monocytes and macrophages express only functional
α7 receptors [1,2,15,16]. The α7 receptor expressed by primary
macrophages has a relative molecular mass of 55 kDa by
western blot (Fig. 3A), identical to that of the neuronal recep-
tor [17,18]. Cotinine-induced suppression of TNF release was
abrogated by pre-treatment with α-bungarotoxin (Fig. 3B),
suggesting that the anti-inflammatory activity of cotinine may
be mediated via the nicotinic acetylcholine receptor α7 subunit.
The importance of α7 nAChR in cotinine-induced immunomo-
dulation is also suggested by the ability of α-bungarotoxin
to block cotinine enhancement of IL-10 release (Fig. 7) and to
abrogate cotinine-induced alterations to PI3K activity (mea-
sured as PIP3 release; Fig. 6).
3.4. The anti-inflammatory potential of cotinine is a PI3K/
GSK-3β-dependent but NF-κB-independent phenomenon
Physiologically relevant doses of cotinine augment IL-10
production in LPS-stimulated monocytes, yet LPS-induced NF-
κB is not affected by cotinine (Fig. 4). Therefore, cotinine
appears to act as an anti-inflammatory agent in an NF-κB-
independent manner. We have previously shown that pharma-
cological inhibition of GSK-3β enhances IL-10 production in
response to LPS [13], and confirm this finding herein (Fig. 4).
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less potent inducer of IL-10 than cotinine (Fig. 4). To explore
this further, we examined the effects of cotinine on the ac-
tivation state of Akt (Ser473) and GSK3-β (Ser9). As shown in
Fig. 5, cotinine enhances levels of phosphorylated (active) Akt
in a PI3K-dependendent manner and augments levels of
phosphorylated (inactive) GSK3-β in P. gingivalis-stimulated
monocytes.
3.5. The cholinergic and PI3K anti-inflammatory pathways are
convergent on cotinine stimulation
Cotinine potently augments the activation of PI3K and the
production of the anti-inflammatory cytokine IL-10. In contrast,
blockade of PI3K abrogates the ability of cotinine to suppress
the inflammatory response (TNF-α) in P. gingivalis-stimulated
cells (Figs. 6A and 7). Moreover, inhibition of the α7 nAChR-
signaling pathway abrogated the ability of cotinine to enhance
PI3K activity (Fig. 6B).
4. Discussion
Borovikova et al have demonstrated that electrical stimula-
tion of the vagus nerve protected against death by LPS toxicity in
mice, and showed that acetylcholine significantly attenuated the
release of TNF, IL-1β, and IL-6 from macrophages [3]. It is
important to note, however, that such vagal protection is
abrogated by splenectomy [19]. Specifically it is the α7 nACh
receptor subtype that appears key to acetylcholine-induced
inflammatory suppression, as we and others have recently
reviewed [20–23]. α7 nAChR-deficient mice are not only
hypersensitive to LPS, producing high amounts of TNF-α, they
also exhibit an exaggerated production of the pro-inflammatory
cytokines IL-1β and IL-6 [4,24]. Furthermore, nicotine-
dependent suppression of TNF release from primary macro-
phages is abrogated by α7 AChR-specific antisense oligonu-
cleotides [4], while selective α7 AChR agonists protect against
severe sepsis [25]. It should be noted that a limitation of the
present study is that we have not confirmed our data, obtained
from primary human cells, in vivo.
Functional AChRs are pentameric and are composed of
multiple combinations of a possible 16 monomer subtypes (α1–
7; α9–10; β1–4; δ; ɛ; and γ) that exhibit divergent phar-
macological behaviors [4,16,26]. nAChR subtype expression
by monocytes and macrophages is highly restricted. The α7
receptor expressed by primary macrophages has a relative
molecular mass of 55 kDa by western blot, identical to that of
the neuronal receptor [17,18]. Of the known AChRs, α7
nAChR exhibits a number of unusual features [27]. First of all,
it can assemble and function as a homopentamer [27,28]; the ion
channel exhibits high permeability for calcium ions in pre-
ference to Na+ [29]; and it is widely expressed in the central and
peripheral nervous system [26] as well as on leukocytes [4].
αBTX is not specific for α7 nAChR. However, of the α-
bungarotoxin sensitive human nAChRs (α1, α7, and α9),
monocytes and macrophages express only functional α7 re-
ceptors [1,2,15,16]. We have been able to use α-bungarotoxin tostrongly suggest that cotinine-induced inflammatory suppres-
sion occurs through the nicotinic acetylcholine receptor α7
subunit. Definitive confirmation of the role of α7 nAChR will
require further experimentation, such as utilizing antisense or
silencing RNA techniques.
We extend existing knowledge by demonstrating that co-
tinine has similar anti-inflammatory properties to its addictive
and toxic catabolic precursor, nicotine, showing that cotinine
blocks the production of multiple pro-inflammatory cytokines
that are known to be under the transcriptional control of NF-κB,
including the innate/adaptive immunity bridging cytokine, IL-
12/IL-23 p40 [30,31]; while simultaneously augmenting the
release of the anti-inflammatory molecule, IL-10; and establish-
ing that these actions of cotinine are likely to be mediated
through the α7 nAChR. The suppression of the p40 subunit
shared by IL-12 and IL23 is particularly interesting as it is
critical for the development of IFN-γ-producing Th1 cells and
influences cell-mediated immunity and IgG2a antibody produc-
tion from B cells [32–35]. Recently, Chen et al have reported
that alveolar macrophages from smokers exhibit a reduced pro-
inflammatory response (TNF-α, IL-1β, IL-6, IL-8) to TLR-2
and TLR-4 agonists (Pam3Cys and LPS, respectively) com-
pared to cells from non-smokers [36].
We next set out to address the mechanisms by which coti-
nine exerts anti-inflammatory effects on innate cells. The NF-κB
pathway is critical in the activation of mononuclear phagocytes
and in the production of multiple pro-inflammatory cytokines by
these cells [30,31]. Limited evidence suggests that nicotine
maintains cytoplasmic concentrations of IκB and thus prevents
LPS-induced NF-κB activation in monocytes and macrophages,
in a dose-dependent manner [3,4,37]. One recent report suggests
that smoking inhibits the TLR-2/-4 inducible phosphorylation of
IRAK-1 and p38 and also inhibits IκB-α degradation [36].
However, our data shows that cotinine appears to act as an anti-
inflammatory agent in an NF-κB-independent manner, as phy-
siologically relevant doses of cotinine augment IL-10 produc-
tion in LPS-stimulated monocytes, yet LPS-induced NF-κB is
not affected by cotinine. Indeed, we demonstrate that cotinine
regulates the phosphorylation of GSK3β (Serine 9) via the
PI3K-Akt pathway. These data are consistent with previous
studies by our laboratory that have shown that GSK3β does not
affect the absolute or phosphorylated (activated) levels of NF-
κB (p65) but affects the levels of CREB (Ser133) that displaces
NF-κB (p65) from the transcriptional complex (CBP) [13]. We
have also previously demonstrated that the levels of CREB
(Ser133) are important for IL-10 production in TLR-stimulated
cells but that the loss of NF-κB (p65) does not affect IL-10 [13].
Once phosphatidylinositol 3 kinase (PI3K) becomes acti-
vated, it catalyzes the production of phosphatidylinositol-3,4,5-
trisphosphate [PIP3]. The generation of PIP3 subsequently
allows for the recruitment and co-localization of phosphoinosi-
tide-dependent kinase 1 (PDK1) and the serine/threonine-
dependent kinase Akt via their pleckstrin homology domains
[38,39]. This co-localization to the plasma membrane allows
for the activation of Akt via the phosphorylation of threonine
308 by PDK1 and phosphorylation at serine 473 by a still
unidentified kinase called PDK2 [38–40]. Upon dual
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multitude of downstream targets including the serine phosphor-
ylation that results in the inhibition of glycogen synthase kinase
3 (Ser21, GSK-3α; and Ser9 GSK-3β) [41]. Previous studies
from our laboratories have identified that the phosphatidylino-
sitol-3 kinase (PI3K) pathway plays a fundamental role in
regulating the host inflammatory response to P. gingivalis by
negatively regulating IL-12 p40/p70 production while concur-
rently augmenting IL-10 levels in a toll like receptor (TLR)-
dependent manner. Sequential downstreammapping of the PI3K
pathway identified that inactivation (by phosphorylation) of the
constitutively active serine/threonine kinase, glycogen synthase
kinase 3, via Akt, is central to the ability of this pathway to
suppress the levels of pro-inflammatory cytokines while
augmenting anti-inflammatory cytokine production (IL-10)
[13]. Thus, the PI3K pathway can act as a central regulator in
modulating the nature (pro- versus anti-inflammatory) and
magnitude (absolute levels) of the host inflammatory response.
However, at this stage it is important to note that this PI3K anti-
inflammatory pathway is normally minimally engaged.
The ability to selectively augment anti-inflammatory cyto-
kine production while concurrently suppressing pro-inflamma-
tory cytokines provides a strong focal point for the elucidation,
characterization, and application of potential therapeutic targets
that could attenuate or modulate the inflammatory disease
process. Thus, we confirmed our previous data that pharmaco-
logical inhibition of GSK-3β enhances IL-10 production in
response to LPS. However, SB216763 inhibition of GSK-3β is a
significantly less potent inducer of IL-10 than even low doses
(10 ng ml− 1) of cotinine, suggesting a convergence of the
cholinergic andGSK-3β-mediated anti-inflammatory pathways.
Indeed, cotinine enhances levels of phosphorylated (active) Akt
in a PI3K-dependent manner and augments levels of phos-
phorylated (inactive) GSK3-β in P. gingivalis-stimulated
monocytes. Inhibition of the α7 nAChR-signaling pathway
abrogated the ability of cotinine to enhance PI3K activity. Thus,
cotinine augments the activity of PI3K via the α7 nAChR.
In summary, we have shown that, in primary human mo-
nocytes, cotinine is a potent anti-inflammatory agent that most
likely acts through the α7 nAChR resulting in a convergence of
the cholinergic anti-inflammatory pathway and an endogenous
PI3K-dependent anti-inflammatory pathway in monocytes. The
PI3K-dependent anti-inflammatory pathway in monocytes is
normally minimally engaged, but signaling through this PI3K-
Akt-GSK-3β route is amplified by cotinine—probably on
engagement of α7 nAChR. As our knowledge of these signaling
interactions increases, we are likely to identify further attractive
anti-inflammatory targets.
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